The Next Generation of Antimicrobials

Novophage’s patent-pending bacteriophages—phages for short—increase the efficacy of antibiotic treatment and extend the lifetime of antibiotics, both clinically and with regards to patent protection. Novophage achieves these advances through the co‐treatment of infections with existing antibiotics and our engineered phages. Our phages attack bacteria and bacteria only, making them safe for human use. They significantly delay the onset of antibiotic resistance by targeting intracellular bacterial processes and circumventing bacterial resistance mechanisms. Novophage is providing the next generation of antimicrobials.